fda warning compounding semaglutide october 2025 is moving to restrict mass-marketed compounded GLP-1 products that aren't FDA-approved, companies they can't market them as equivalent to approved drugs and signaling stronger enforcement to protect patients from unverified FDA issued 25 warning letters

Ultimately, less oversight across the boardin terms of process and productmakes any compounded drug an inherently riskier choice than a commercial option reviewed by the FDA

Survodutide, which activates both glucagon-like peptide-1 (GLP-1) and glucagon receptors, demonstrated significant and sustained weight loss

Innovation in delivery systems Lonza Consumer Health & Nutrition invests significantly in its research and development program, to ensure that its ingredients and dosage forms are backed by science and to accelerate speed-to-market for new products

Month 4 onwards: Full exercise capacity typically available

Li G, Huang X

ILLEGAL SALES Few realise that a doctors prescription is required, as these drugs can cause side effects such as nausea, gallstone disease and eye conditions